Targeting SERT promotes tryptophan metabolism: mechanisms and implications in colon cancer treatment

• Published in: Journal of experimental & clinical cancer research Vol. 40; no. 1; p. 173
• Main Authors: Ye, Di, Xu, Huanji, Xia, Hongwei, Zhang, Chenliang, Tang, Qiulin, Bi, Feng
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 18.05.2021; BioMed Central; BMC
• Subjects: Analysis; Animals; Antibodies; Asenapine; Biosynthesis; Cancer; Care and treatment; Cell growth; Cell Line, Tumor; Colon cancer; Colonic Neoplasms - drug therapy; Colorectal cancer; Development and progression; Drug therapy; Female; Gene expression; Homeostasis; Humans; Liquid chromatography; Mass spectrometry; Metabolism; Metabolites; Mice; Mice, Nude; mTORC1; Physiological aspects; Proteins; Serotonin; Serotonin Plasma Membrane Transport Proteins - metabolism; SERT; Signal Transduction; Targeted cancer therapy; Thermal cycling; Trametinib; Transfection; Tryptophan; Tryptophan - metabolism; Tryptophan - pharmacology; Tryptophan - therapeutic use; Tumorigenesis; Tumors; China; United States > US; Japan; Tryptophan; SERT; Serotonin; mTORC1; Trametinib
• ISSN: 1756-9966; 0392-9078; 1756-9966
• DOI: 10.1186/s13046-021-01971-1

Serotonin signaling has been associated with tumorigenesis and tumor progression. Targeting the serotonin transporter to block serotonin cellular uptake confers antineoplastic effects in various tumors, including colon cancer. However, the antineoplastic mechanism of serotonin transporter inhibition and serotonin metabolism alterations in the absence of serotonin transporter have not been elucidated, especially in colon cancer, which might limit anti-tumor effects associating with targeting serotonin transporter. The promotion in the uptake and catabolism of extracellular tryptophan and targeting serotonin transporter was detected by using quantitative reverse-transcription polymerase chain reaction, western blotting and liquid chromatography tandem mass spectrometry. Western blotting Immunoprecipitation and immunofluorescence was utilized to research the serotonylation of mTOR by serotonin and serotonin transporter inhibition. The primary mouse model, homograft model and tissue microarry was used to explore the tryptophan pathway in colon cancer. The cell viability assay, western blotting, xenograft and primary colon cancer mouse model were used to identify whether the combination of sertraline and tryptophan restriction had a synergistic effect. Targeting serotonin transporter through genetic ablation or pharmacological inhibition in vitro and in vivo induced a compensatory effect by promoting the uptake and catabolism of extracellular tryptophan in colon cancer. Mechanistically, targeting serotonin transporter suppressed mTOR serotonylation, leading to mTOR inactivation and increased tryptophan uptake. In turn, this process promoted serotonin biosynthesis and oncogenic metabolite kynurenine production through enhanced tryptophan catabolism. Tryptophan deprivation, or blocking its uptake by using trametinib, a MEK inhibitor, can sensitize colon cancer to selective serotonin reuptake inhibitors. The present study elucidated a novel feedback mechanism involved in the regulation of serotonin homeostasis and suggested innovative strategies for selective serotonin reuptake inhibitors-based treatment of colon cancer.